Yalowich JC |
Effects of microtubule inhibitors on etoposide accumulation and DNA damage in human K562 cells in vitro. |
1987 |
Cancer Res. |
pmid:2879622
|
Takahashi M et al. |
Rhizoxin binding to tubulin at the maytansine-binding site. |
1987 |
Biochim. Biophys. Acta |
pmid:3120782
|
Yang JL et al. |
[Antitumor activity of trewiasine in vitro and in vivo]. |
1988 |
Zhongguo Yao Li Xue Bao |
pmid:3256213
|
Sakai K et al. |
Antitumor principles in mosses: the first isolation and identification of maytansinoids, including a novel 15-methoxyansamitocin P-3. |
1988 Sep-Oct |
J. Nat. Prod. |
pmid:3204376
|
Ludueña RF et al. |
The interaction of phomopsin A with bovine brain tubulin. |
1989 |
Arch. Biochem. Biophys. |
pmid:2735765
|
Bai RL et al. |
Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. |
1990 |
J. Biol. Chem. |
pmid:2211617
|
Dymowski W and Furmanowa M |
[Investigating cytostatic substances in tissue of plants Maytenus Molina in in-vitro cultures. II. chromatographic test of extracts from callus of Maytenus wallichiana R. et B]. |
1990 |
Acta Pol Pharm |
pmid:1669332
|
Sullivan AS et al. |
Interaction of rhizoxin with bovine brain tubulin. |
1990 |
Cancer Res. |
pmid:2364385
|
Suwanborirux K et al. |
Ansamitocin P-3, a maytansinoid, from Claopodium crispifolium and Anomodon attenuatus or associated actinomycetes. |
1990 |
Experientia |
pmid:2298279
|
Ludueña RF et al. |
Effect of phomopsin A on the alkylation of tubulin. |
1990 |
Biochem. Pharmacol. |
pmid:2337418
|
Kuo YH et al. |
Antitumor agents, 112. Emarginatine B, a novel potent cytotoxic sesquiterpene pyridine alkaloid from Maytenus emarginata. |
1990 Mar-Apr |
J. Nat. Prod. |
pmid:2380715
|
Bai RL et al. |
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. |
1991 |
J. Biol. Chem. |
pmid:1874739
|
Mujagić H and Mujagić Z |
Detection of pleiotropic drug resistance by the rapid immunofluorescence assay of drug effects on the cell skeleton. |
1991 |
Oncology |
pmid:2023698
|
Tan GT et al. |
Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. |
1991 Jan-Feb |
J. Nat. Prod. |
pmid:1710653
|
Okamoto K et al. |
Therapeutic effect of ansamitocin targeted to tumor by a bispecific monoclonal antibody. |
1992 |
Jpn. J. Cancer Res. |
pmid:1517150
|
Yue XF et al. |
Cytotoxic activity of trewiasine in 4 human cancer cell lines and 5 murine tumors. |
1992 |
Zhongguo Yao Li Xue Bao |
pmid:1442109
|
Chari RV et al. |
Immunoconjugates containing novel maytansinoids: promising anticancer drugs. |
1992 |
Cancer Res. |
pmid:1727373
|
Li Y et al. |
Binding selectivity of rhizoxin, phomopsin A, vinblastine, and ansamitocin P-3 to fungal tubulins: differential interactions of these antimitotic agents with brain and fungal tubulins. |
1992 |
Biochem. Biophys. Res. Commun. |
pmid:1530630
|
Li Y et al. |
Interaction of phomopsin A with porcine brain tubulin. Inhibition of tubulin polymerization and binding at a rhizoxin binding site. |
1992 |
Biochem. Pharmacol. |
pmid:1739410
|
Hamel E |
Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. |
1992 |
Pharmacol. Ther. |
pmid:1287674
|
Novelo M et al. |
Cytotoxic constituents from Hyptis verticillata. |
1993 |
J. Nat. Prod. |
pmid:8277312
|
Iwasaki S |
[Inhibitors of tubulin assembly: specially on rhizoxin-maytansine site ligands]. |
1993 |
Tanpakushitsu Kakusan Koso |
pmid:8210422
|
Sawada T et al. |
A fluorescent probe and a photoaffinity labeling reagent to study the binding site of maytansine and rhizoxin on tubulin. |
1993 Jul-Aug |
Bioconjug. Chem. |
pmid:8218485
|
David B et al. |
Rhazinilam mimics the cellular effects of taxol by different mechanisms of action. |
1994 |
Cell Motil. Cytoskeleton |
pmid:7954858
|
Sinha S and Jain S |
Natural products as anticancer agents. |
1994 |
Prog Drug Res |
pmid:7916160
|
Fellous A et al. |
Removal of the projection domain of microtubule-associated protein 2 alters its interaction with tubulin. |
1994 |
J. Protein Chem. |
pmid:7986343
|
Liu C et al. |
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. |
1996 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:8710920
|
Ladino CA et al. |
Folate-maytansinoids: target-selective drugs of low molecular weight. |
1997 |
Int. J. Cancer |
pmid:9399666
|
Rai SS and Wolff J |
The C terminus of beta-tubulin regulates vinblastine-induced tubulin polymerization. |
1998 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:9539723
|
Jordan A et al. |
Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. |
1998 |
Med Res Rev |
pmid:9664292
|
Werbovetz KA et al. |
Purification, characterization, and drug susceptibility of tubulin from Leishmania. |
1999 |
Mol. Biochem. Parasitol. |
pmid:10029309
|
Havens CG et al. |
Cellular effects of leishmanial tubulin inhibitors on L. donovani. |
2000 |
Mol. Biochem. Parasitol. |
pmid:11071278
|
Monneret C and Florent JC |
[Targeting of antitumor drugs with monoclonal antibodies]. |
2000 |
Bull Cancer |
pmid:11125291
|
Smith S |
Technology evaluation: C242-DM1, ImmunoGen Inc. |
2001 |
Curr. Opin. Mol. Ther. |
pmid:11338934
|
Ross S et al. |
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. |
2002 |
Cancer Res. |
pmid:11980648
|
Carroll BJ et al. |
Identification of a set of genes involved in the formation of the substrate for the incorporation of the unusual "glycolate" chain extension unit in ansamitocin biosynthesis. |
2002 |
J. Am. Chem. Soc. |
pmid:11960423
|
Yu TW et al. |
The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum. |
2002 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:12060743
|
Moss SJ et al. |
Identification of asm19 as an acyltransferase attaching the biologically essential ester side chain of ansamitocins using N-desmethyl-4,5-desepoxymaytansinol, not maytansinol, as its substrate. |
2002 |
J. Am. Chem. Soc. |
pmid:12047169
|
Ranson M and Sliwkowski MX |
Perspectives on anti-HER monoclonal antibodies. |
2002 |
Oncology |
pmid:12422051
|
Cruz-Monserrate Z et al. |
Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography. |
2003 |
Eur. J. Biochem. |
pmid:12950266
|
Pullen CB et al. |
Occurrence and non-detectability of maytansinoids in individual plants of the genera Maytenus and Putterlickia. |
2003 |
Phytochemistry |
pmid:12620351
|
Tolcher AW et al. |
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. |
2003 |
J. Clin. Oncol. |
pmid:12525512
|
Spiteller P et al. |
The post-polyketide synthase modification steps in the biosynthesis of the antitumor agent ansamitocin by Actinosynnema pretiosum. |
2003 |
J. Am. Chem. Soc. |
pmid:14624546
|
Xie H et al. |
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. |
2004 |
J. Pharmacol. Exp. Ther. |
pmid:14634038
|
Tassone P et al. |
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. |
2004 |
Blood |
pmid:15292058
|
Lu C et al. |
A novel amide N-glycoside of ansamitocins from Actinosynnema pretiosum. |
2004 |
J. Antibiot. |
pmid:15303496
|
Nakao H et al. |
Cytotoxic activity of maytanprine isolated from Maytenus diversifolia in human leukemia K562 cells. |
2004 |
Biol. Pharm. Bull. |
pmid:15305028
|
Helft PR et al. |
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. |
2004 |
Clin. Cancer Res. |
pmid:15240523
|
Tassone P et al. |
In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. |
2004 |
Cancer Res. |
pmid:15231675
|
Cassady JM et al. |
Recent developments in the maytansinoid antitumor agents. |
2004 |
Chem. Pharm. Bull. |
pmid:14709862
|
Liu Z et al. |
An API LC/MS/MS quantitation method for ansamitocin P-3 (AP3) and its preclinical pharmacokinetics. |
2004 |
J Pharm Biomed Anal |
pmid:15533675
|
Henry MD et al. |
A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. |
2004 |
Cancer Res. |
pmid:15520207
|
Smith SV |
Technology evaluation: cantuzumab mertansine, ImmunoGen. |
2004 |
Curr. Opin. Mol. Ther. |
pmid:15663331
|
Fleming MS et al. |
A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. |
2005 |
Anal. Biochem. |
pmid:15840500
|
Wang L et al. |
Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. |
2005 |
Protein Sci. |
pmid:16081651
|
Smith SV |
Technology evaluation: huN901-DM1, ImmunoGen. |
2005 |
Curr. Opin. Mol. Ther. |
pmid:16121706
|
Liu Z et al. |
Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. |
2005 |
J Mass Spectrom |
pmid:15674857
|
Lu SX et al. |
Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. |
2005 |
J Pharm Sci |
pmid:15729708
|
Lazar AC et al. |
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. |
2005 |
Rapid Commun. Mass Spectrom. |
pmid:15945030
|
Frenzel T et al. |
Synthesis of the N-acetylcysteamine thioester of seco-proansamitocin. |
2006 |
Org. Lett. |
pmid:16381586
|
Kubota T et al. |
Determination of the cryptic stereochemistry of the first PKS chain-extension step in ansamitocin biosynthesis by Actinosynnema pretiosum. |
2006 |
Chembiochem |
pmid:16927319
|
Tijink BM et al. |
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. |
2006 |
Clin. Cancer Res. |
pmid:17062682
|
Kovtun YV et al. |
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. |
2006 |
Cancer Res. |
pmid:16540673
|
Floss HG |
Combinatorial biosynthesis--potential and problems. |
2006 |
J. Biotechnol. |
pmid:16414140
|
Erickson HK et al. |
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. |
2006 |
Cancer Res. |
pmid:16618769
|
Widdison WC et al. |
Semisynthetic maytansine analogues for the targeted treatment of cancer. |
2006 |
J. Med. Chem. |
pmid:16821799
|
Wenzel SC et al. |
On the biosynthetic origin of methoxymalonyl-acyl carrier protein, the substrate for incorporation of "glycolate" units into ansamitocin and soraphen A. |
2006 |
J. Am. Chem. Soc. |
pmid:17076505
|
Snipes CE et al. |
The ansacarbamitocins: polar ansamitocin derivatives. |
2007 |
J. Nat. Prod. |
pmid:17892263
|
Goh S et al. |
An integrative expression vector for Actinosynnema pretiosum. |
2007 |
BMC Biotechnol. |
pmid:17956638
|
Sauter A et al. |
Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. |
2007 |
Int. J. Oncol. |
pmid:17332932
|
Meyer A et al. |
Chemoenzymatic approaches toward dechloroansamitocin P-3. |
2007 |
Org. Lett. |
pmid:17378571
|
Ma J et al. |
New amide N-glycosides of ansamitocins identified from Actinosynnema pretiosum. |
2007 |
Arch. Pharm. Res. |
pmid:17679541
|
Reddy JA et al. |
Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. |
2007 |
Cancer Res. |
pmid:17616697
|
Galsky MD et al. |
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. |
2008 |
J. Clin. Oncol. |
pmid:18362364
|
Arai MA et al. |
Hedgehog/GLI-mediated transcriptional inhibitors from Zizyphus cambodiana. |
2008 |
Bioorg. Med. Chem. |
pmid:18842418
|
Lewis Phillips GD et al. |
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. |
2008 |
Cancer Res. |
pmid:19010901
|
Riechelmann H et al. |
Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. |
2008 |
Oral Oncol. |
pmid:18203652
|
Chari RV |
Targeted cancer therapy: conferring specificity to cytotoxic drugs. |
2008 |
Acc. Chem. Res. |
pmid:17705444
|
Rodon J et al. |
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. |
2008 |
Cancer Chemother. Pharmacol. |
pmid:18301896
|
Ishitsuka K et al. |
Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. |
2008 |
Br. J. Haematol. |
pmid:18279455
|
Taft F et al. |
Highly active ansamitocin derivatives: mutasynthesis using an AHBA-blocked mutant. |
2008 |
Chembiochem |
pmid:18381586
|
Ostermann E et al. |
Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. |
2008 |
Clin. Cancer Res. |
pmid:18628473
|
Stephan JP et al. |
Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. |
2008 |
Bioconjug. Chem. |
pmid:18637680
|
Zhao P et al. |
Amide N-glycosylation by Asm25, an N-glycosyltransferase of ansamitocins. |
2008 |
Chem. Biol. |
pmid:18721757
|
Polson AG et al. |
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. |
2009 |
Cancer Res. |
pmid:19258515
|
Taft F et al. |
Timing of the Delta(10,12)-Delta(11,13) double bond migration during ansamitocin biosynthesis in Actinosynnema pretiosum. |
2009 |
J. Am. Chem. Soc. |
pmid:19292483
|
Wang L et al. |
Formal total synthesis of N-methylmaysenine. |
2009 |
Org. Lett. |
pmid:19296671
|
Ikeda H et al. |
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. |
2009 |
Clin. Cancer Res. |
pmid:19509164
|
Al-Katib AM et al. |
Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. |
2009 |
Clin. Cancer Res. |
pmid:19509168
|
Tang R et al. |
P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. |
2009 |
BMC Cancer |
pmid:19549303
|
Ng D et al. |
Constitutive overexpression of asm2 and asm39 increases AP-3 production in the actinomycete Actinosynnema pretiosum. |
2009 |
J. Ind. Microbiol. Biotechnol. |
pmid:19609582
|
Zheng B et al. |
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. |
2009 |
Mol. Cancer Ther. |
pmid:19808977
|
Haeuw JF et al. |
[Immunoconjugates, drug-armed antibodies to fight against cancer]. |
2009 |
Med Sci (Paris) |
pmid:20035677
|
Lutz RJ and Whiteman KR |
Antibody-maytansinoid conjugates for the treatment of myeloma. |
2009 Nov-Dec |
MAbs |
pmid:20068397
|
Monneret C |
[Current impact of natural products in the discovery of anticancer drugs]. |
2010 |
Ann Pharm Fr |
pmid:20637355
|
Higa GM et al. |
Biological considerations and clinical applications of new HER2-targeted agents. |
2010 |
Expert Rev Anticancer Ther |
pmid:20836684
|
Wei GZ et al. |
A new antitumour ansamitocin from Actinosynnema pretiosum. |
2010 |
Nat. Prod. Res. |
pmid:20582809
|
Kovtun YV et al. |
Antibody-maytansinoid conjugates designed to bypass multidrug resistance. |
2010 |
Cancer Res. |
pmid:20197459
|
Krop IE et al. |
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. |
2010 |
J. Clin. Oncol. |
pmid:20421541
|
Jumbe NL et al. |
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. |
2010 |
J Pharmacokinet Pharmacodyn |
pmid:20424896
|